Kodiak Sciences Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Stock-Based Compensation
- Stock-Based Compensation
Shares of common stock available for issuance under the Company's equity incentive plans at June 30, 2026, were as follows:
| Outstanding stock awards | 21,658,848 |
|---|---|
| Reserved for future award grants | 2,769,357 |
| Reserved for future ESPP purchases | 230,311 |
| Total | 24,658,516 |
Stock Options
Stock option activity, including stock options and performance-based stock options under the 2021 Long-Term Performance Incentive Plan (“LTPIP”), 2018 Equity Incentive Plan ("2018 Plan") and 2015 Share Incentive Plan is summarized as follows:
| NumberofOptions | WeightedAverageExercisePrice | WeightedAverageRemainingContractualTerm (in years) | AggregateIntrinsicValue(in thousands) | |
|---|---|---|---|---|
| Outstanding at December 31, 2025 | 22,223,236 | $32.42 | 6.43 | $328,282 |
| Granted | 421,886 | $31.96 | ||
| Exercised | (1,012,665) | $3.60 | ||
| Forfeited or canceled | (100,360) | $6.84 | ||
| Outstanding at June 30, 2026 | 21,532,097 | $33.88 | 6.07 | $453,300 |
Restricted Shares
Restricted stock units activity under the 2018 Plan is summarized as follows:
| Number ofRestrictedShares | WeightedAverageGrant DateFair Value | |
|---|---|---|
| Unvested at December 31, 2025 | 120,820 | $5.58 |
| Granted | 37,200 | 36.29 |
| Vested | (25,194) | 6.46 |
| Canceled | (6,075) | 9.79 |
| Unvested at June 30, 2026 | 126,751 | $14.22 |
Stock-Based Compensation Expense
Stock-based compensation is classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Research and development | $5,836 | $7,714 | $12,025 | $15,572 |
| General and administrative | 5,772 | 7,927 | 11,738 | 15,960 |
| Total stock-based compensation | $11,608 | $15,641 | $23,763 | $31,532 |
The following is a summary of stock-based compensation expense by award type (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| LTPIP Program | $8,513 | $12,718 | $17,970 | $25,641 |
| Stock Options | 2,547 | 2,554 | 5,087 | 5,130 |
| Performance-based awards | 383 | — | 438 | 12 |
| RSUs | 109 | 336 | 178 | 684 |
| ESPP | 56 | 33 | 90 | 65 |
| Total stock-based compensation | $11,608 | $15,641 | $23,763 | $31,532 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.